Save

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

PHASE2RECRUITING

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks).

Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study, participants will visit their study clinic several times.

Simpliy with AI

Study details:

Study TAK-279-UC-2001 is a multicenter, randomized, placebo-controlled, study with a 12-week double-blinded induction treatment period, a 40-week open-label treatment period (52 total weeks of treatment), and a 4-week safety follow-up period. An approximate total of eligible 207 participants will be randomized to one of the three treatment groups -. 1.

TAK-279 Dose 1. 2. TAK-279 Dose 2.

3. Placebo. The maximum study duration per participant is approximately 60 weeks, including up to 30 days for the screening period, a 12-week randomized and double-blinded induction treatment period, a 40-week open-label treatment period, and a 4-week safety follow-up period.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Male or female aged 18-75 years old with diagnosis of UC for at least 30 days. In South Korea, the age requirement for adult participants is ≥19 years of age.

Confirmed diagnosis of moderately to severely active UC assessed by mMS and ES.

Participants with a history of inadequate response to, loss of response to, or intolerance to one or more of conventional, biologic or advance therapies for UC.

Participants must meet the contraception recommendations.

Exclusion criteria

Participants with indeterminate/unclassified inflammatory bowel disease (IBD), microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, diverticular disease associated with colitis, and/or clinical/histologic findings suggestive of Crohn's disease (CD).

Participants with complications of UC such as strictures, stenoses, fistulas, short gut syndrome, or any other manifestation that might require surgery during the study.

Participants with a current ileostomy or colostomy. Participants who had a J-pouch are excluded, as a J-pouch could result in a stoma.

Participants who have failed 3 or more classes of advanced therapies.

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2024-03-29

Primary completion: 2026-09-30

Study completion finish: 2027-08-04

Study type

TREATMENT

Phase

PHASE2

Trial ID

NCT06254950

Intervention or treatment

DRUG: TAK-279

DRUG: Placebo

Conditions

• Ulcerative Colitis

Condition: Ulcerative Colitis
DRUG: TAK-279 and other drugs
Kingswood, New South Wales, Australia and more
Sponsor: Takeda

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Nepean Clinical School

Research sites nearby

Select from list below to view details:

Nepean Clinical School
Kingswood, New South Wales, Australia
Concord Repatriation General Hospital
Sydney, New South Wales, Australia
Western Health/Footscray Hospital
Melbourne, Victoria, Australia
Harry Perkins Medical Research Institute Fiona Stanley Hospital
Murdoch, Not Specified, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: TAK-279 Dose 1 TAK-279, capsules, orally at Dose 1 up to Week 12 followed by either Dose 1 or Dose 2 up to week 52 based on the response.	DRUG: TAK-279 TAK-279 capsules.
EXPERIMENTAL: TAK-279 Dose 2 TAK-279, capsules, orally at Dose 2 up to Week 12 followed by either Dose 1 or Dose 2 up to week 52 based on the response.	DRUG: TAK-279 TAK-279 capsules.
PLACEBO_COMPARATOR: Placebo TAK-279 matching placebo capsules, orally, for 12 weeks followed by TAK-279 capsules, orally either Dose 1 or Dose 2 up to Week 52 based on the response.	DRUG: TAK-279 TAK-279 capsules.

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Percentage of Participants Achieving Clinical Remission at Week 12 Based on Modified Mayo Score (mMS)	The mMS is a composite score of 3 assessments consisting of stool frequency (SF), rectal bleeding (RB), and endoscopic score (ES). Each component subscore ranges from 0 to 3 and total score range of the mMS is from 0 to 9, with higher scores indicating more severe disease. Clinical remission is defined an mMS of ≤2 with SF subscore ≤ 1, RB subscore = 0, and ES ≤ 1 (score of 1 modified to exclude friability).	Week 12

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Percentage of Participants Achieving Clinical Response at Week 12 Based on Modified Mayo Score (mMS)	Clinical response defined as reduction from baseline in mMS of ≥2 points and ≥30% from baseline and a decrease from baseline in the RB subscore of ≥1 point or an absolute RB subscore of ≤1 point at Week 12.	Baseline, Week 12
Percentage of Participants Achieving Symptomatic Remission at Week 12	Symptomatic remission is defined as a RB subscore of 0 and SF subscore of ≤1.	Week 12
Percentage of Participants Achieving Endoscopic Improvement at Week 12	Endoscopic improvement defined as a modified Mayo ES of ≤1 (score of 1 modified to exclude friability).	Week 12
Percentage of Participants Achieving Endoscopic Remission at Week 12	Endoscopic remission defined as a modified Mayo ES of 0.	Week 12
Percentage of Participants With no Bowel Urgency at Week 12	Bowel urgency measured by the bowel urgency electronic diary (eDiary) item at Week 12.	Week 12
Percentage of Participants With no Abdominal Pain at Week 12	Abdominal pain measured by abdominal pain eDiary item at Week 12.	Week 12
Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score ≥170 at Week 12	The IBDQ is a 32-item questionnaire that measures 4 dimensions: bowel function (10 items), emotional status (12 items), systemic symptoms (5 items), and social function (5 items). The total score ranges from 32 to 224, with higher scores representing better quality of life.	Week 12
Change From Baseline in Disease-Specific Health-related Quality of Life (HRQoL) as Measured by IBDQ Total Score at Week 12	The IBDQ is a 32-item questionnaire that measures 4 dimensions: bowel function (10 items), emotional status (12 items), systemic symptoms (5 items), and social function (5 items). The total score ranges from 32 to 224, with higher scores representing better quality of life.	Baseline and Week 12
Change From Baseline in Fatigue as Measured by the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 12	The FACIT-Fatigue is a reliable and valid instrument for measuring fatigue. The responses to the 13 items on the FACIT-Fatigue questionnaire are each measured on a 5-point Likert scale, where 0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit and 4=Very much. The total score ranges from 0 to 52. High scores represent less fatigue.	Baseline and Week 12

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis